
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3082684/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Role of diet in regulating the gut microbiota and multiple sclerosis. Clinical Immunology, 2022, 235, 108379.	3.2	19
2	Viral mouse models used to study multiple sclerosis: past and present. Archives of Virology, 2021, 166, 1015-1033.	2.1	13
3	The CSF1R-Microglia Axis Has Protective Host-Specific Roles During Neurotropic Picornavirus Infection. Frontiers in Immunology, 2021, 12, 621090.	4.8	10
4	Molecular patterns from a human gut-derived Lactobacillus strain suppress pathogenic infiltration of leukocytes into the central nervous system. Journal of Neuroinflammation, 2020, 17, 291.	7.2	5
5	Modulation of experimental autoimmune encephalomyelitis through colonisation of the gut with Escherichia coli. Beneficial Microbes, 2020, 11, 669-684.	2.4	5
6	Viral Triggers and Inflammatory Mechanisms in Pediatric Epilepsy. Molecular Neurobiology, 2019, 56, 1897-1907.	4.0	24
7	Differential transcriptional profiles identify microglial- and macrophage-specific gene markers expressed during virus-induced neuroinflammation. Journal of Neuroinflammation, 2019, 16, 152.	7.2	93
8	Depletion of PD-1-positive cells ameliorates autoimmune disease. Nature Biomedical Engineering, 2019, 3, 292-305.	22.5	48
9	Microglial cell depletion is fatal with low levelÂpicornavirus infection of the central nervous system. Journal of NeuroVirology, 2019, 25, 415-421.	2.1	34
10	Positive modulation of mGluR5 attenuates seizures and reduces TNF-α+ macrophages and microglia in the brain in a murine model of virus-induced temporal lobe epilepsy. Experimental Neurology, 2019, 311, 194-204.	4.1	20
11	The microbiota protects from viral-induced neurologic damage through microglia-intrinsic TLR signaling. ELife, 2019, 8, .	6.0	41
12	Variations in diet cause alterations in microbiota and metabolites that follow changes in disease severity in a multiple sclerosis model. Beneficial Microbes, 2018, 9, 495-513.	2.4	33
13	The immune response to picornavirus infection and the effect of immune manipulation on acute seizures. Journal of NeuroVirology, 2018, 24, 464-477.	2.1	19
14	Induced CNS expression of CXCL1 augments neurologic disease in a murine model of multiple sclerosis via enhanced neutrophil recruitment. European Journal of Immunology, 2018, 48, 1199-1210.	2.9	33
15	Diffusion Basis Spectrum and Diffusion Tensor Imaging Detect Hippocampal Inflammation and Dendritic Injury in a Virus-Induced Mouse Model of Epilepsy. Frontiers in Neuroscience, 2018, 12, 77.	2.8	23
16	Theiler's murine encephalomyelitis virus infection of SJL/J and C57BL/6J mice: Models for multiple sclerosis and epilepsy. Journal of Neuroimmunology, 2017, 308, 30-42.	2.3	64
17	Complement Components Are Expressed by Infiltrating Macrophages/Activated Microglia Early Following Viral Infection. Viral Immunology, 2017, 30, 304-314.	1.3	7
18	Microbiota promotes systemic T-cell survival through suppression of an apoptotic factor. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 5497-5502.	7.1	23

#	Article	IF	CITATIONS
19	The role of peripheral interleukin-6 in the development of acute seizures following virus encephalitis. Journal of NeuroVirology, 2017, 23, 696-703.	2.1	19
20	Hippocampal TNFα Signaling Contributes to Seizure Generation in an Infection-Induced Mouse Model of Limbic Epilepsy. ENeuro, 2017, 4, ENEURO.0105-17.2017.	1.9	88
21	Complete Genome Sequence of Murine Pneumotropic Virus (<i>Polyomaviridae</i>) Clone pKV(37-1). Genome Announcements, 2016, 4, .	0.8	1
22	NBQX, a highly selective competitive antagonist of AMPA and KA ionotropic glutamate receptors, increases seizures and mortality following picornavirus infection. Experimental Neurology, 2016, 280, 89-96.	4.1	28
23	Variable Genome Sequences of the Murine Pneumotropic Virus (<i>Polyomaviridae</i>) Regulatory Region Isolated from an Infected Mouse Tissue Viral Suspension. Genome Announcements, 2016, 4, .	0.8	Ο
24	The effects of diet on the severity of central nervous system disease: One part of lab-to-lab variability. Nutrition, 2016, 32, 877-883.	2.4	12
25	Infections, inflammation and epilepsy. Acta Neuropathologica, 2016, 131, 211-234.	7.7	348
26	Acthar gel treatment suppresses acute exacerbations in a murine model of relapsing-remitting multiple sclerosis. Autoimmunity, 2015, 48, 222-230.	2.6	12
27	Targeting Insulin-Like Growth Factor 1 Leads to Amelioration of Inflammatory Demyelinating Disease. PLoS ONE, 2014, 9, e94486.	2.5	10
28	Adaptive Immune Responses. , 2014, , 303-319.		3
29	DA virus mutant H101 has altered CNS pathogenesis and causes immunosuppression. Journal of Neuroimmunology, 2014, 277, 118-126.	2.3	4
30	Reviews in neuroimmunology. Journal of NeuroVirology, 2014, 20, 105-106.	2.1	0
31	Role of Pathogens in Multiple Sclerosis. International Reviews of Immunology, 2014, 33, 266-283.	3.3	109
32	Adaptive immune response to viral infections in the central nervous system. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 123, 225-247.	1.8	28
33	Picornavirus infection leading to immunosuppression. Future Virology, 2014, 9, 475-482.	1.8	6
34	Axonal pathology and demyelination in viral models of multiple sclerosis. Discovery Medicine, 2014, 18, 79-89.	0.5	23
35	Infiltrating Macrophages Are Key to the Development of Seizures following Virus Infection. Journal of Virology, 2013, 87, 1849-1860.	3.4	92
36	Discovery of Biologically Active Oncologic and Immunologic Small Molecule Therapies using Zebrafish: Overview and Example of Modulation of T Cell Activation. Current Protocols in Pharmacology, 2013, 60, Unit14.24.	4.0	3

#	Article	IF	CITATIONS
37	CD4+T-cell engagement by both wild-type and variant HCV peptides modulates the conversion of viral clearing helper T cells to Tregs. Future Virology, 2013, 8, 695-705.	1.8	1
38	Multiple sclerosis. Current Opinion in Rheumatology, 2013, 25, 496-501.	4.3	51
39	Theiler's murine encephalomyelitis virus contrasts with encephalomyocarditis and foot-and-mouth disease viruses in its functional utilization of the StopGo non-standard translation mechanism. Journal of General Virology, 2013, 94, 348-353.	2.9	9
40	Possible role of interleukin-17 in a prime/challenge model of multiple sclerosis. Journal of NeuroVirology, 2012, 18, 471-478.	2.1	2
41	Antiviral CD8+ T cells cause an experimental autoimmune encephalomyelitis-like disease in naive mice. Journal of NeuroVirology, 2012, 18, 45-54.	2.1	14
42	The activity within the CA3 excitatory network during Theiler's virus encephalitis is distinct from that observed during chronic epilepsy. Journal of NeuroVirology, 2012, 18, 30-44.	2.1	23
43	Immunization with structural and non-structural proteins of Theiler's murine encephalomyelitis virus alters demyelinating disease. Journal of NeuroVirology, 2012, 18, 127-137.	2.1	4
44	Human T cell expansion and experimental autoimmune encephalomyelitis inhibited by Lenaldekar, a small molecule discovered in a zebrafish screen. Journal of Neuroimmunology, 2012, 244, 35-44.	2.3	17
45	Molecular Mimicry as a Mechanism of Autoimmune Disease. Clinical Reviews in Allergy and Immunology, 2012, 42, 102-111.	6.5	424
46	Experimental autoimmune encephalomyelitis as a testing paradigm for adjuvants and vaccines. Vaccine, 2011, 29, 3356-3362.	3.8	30
47	Once initiated, viral encephalitis-induced seizures are consistent no matter the treatment or lack of interleukin-6. Journal of NeuroVirology, 2011, 17, 496-499.	2.1	18
48	Neurotropic viral infections leading to epilepsy: focus on Theiler's murine encephalomyelitis virus. Future Virology, 2011, 6, 1339-1350.	1.8	63
49	Lack of Correlation of Central Nervous System Inflammation and Neuropathology with the Development of Seizures following Acute Virus Infection. Journal of Virology, 2011, 85, 8149-8157.	3.4	28
50	Interleukin-6, Produced by Resident Cells of the Central Nervous System and Infiltrating Cells, Contributes to the Development of Seizures following Viral Infection. Journal of Virology, 2011, 85, 6913-6922.	3.4	94
51	Theiler's virus infection chronically alters seizure susceptibility. Epilepsia, 2010, 51, 1418-1428.	5.1	71
52	Development of Postinfection Epilepsy After Theiler's Virus Infection of C57BL/6 Mice. Journal of Neuropathology and Experimental Neurology, 2010, 69, 1210-1219.	1.7	101
53	Role for antibodies in altering behavior and movement. Autism Research, 2010, 3, 147-152.	3.8	21
54	Neuropathogenesis of Theiler's Murine Encephalomyelitis Virus Infection, An Animal Model for Multiple Sclerosis. Journal of NeuroImmune Pharmacology, 2010, 5, 355-369.	4.1	96

#	Article	IF	CITATIONS
55	Studies in the Modulation of Experimental Autoimmune Encephalomyelitis. Journal of NeuroImmune Pharmacology, 2010, 5, 168-175.	4.1	15
56	Innate but not adaptive immune responses contribute to behavioral seizures following viral infection. Epilepsia, 2010, 51, 454-464.	5.1	102
57	Role for Complement in the Development of Seizures following Acute Viral Infection. Journal of Virology, 2010, 84, 6452-6460.	3.4	44
58	Potential Triggers of MS. Results and Problems in Cell Differentiation, 2009, 51, 21-42.	0.7	40
59	Theiler's murine encephalomyelitis virus attachment to the gastrointestinal tract is associated with sialic acid binding. Journal of NeuroVirology, 2009, 15, 81-89.	2.1	10
60	Contrasting roles for Vα14+natural killer T cells in a viral model for multiple sclerosis. Journal of NeuroVirology, 2009, 15, 90-98.	2.1	11
61	How Relevant are GFAP Autoantibodies in Autism and Tourette Syndrome?. Journal of Autism and Developmental Disorders, 2008, 38, 333-341.	2.7	26
62	Are There Enhanced MBP Autoantibodies in Autism?. Journal of Autism and Developmental Disorders, 2008, 38, 324-332.	2.7	23
63	Seizures following picornavirus infection. Epilepsia, 2008, 49, 1066-1074.	5.1	103
64	Role of B:T cell ratio in suppression of clinical signs: A model for silent MS. Experimental and Molecular Pathology, 2008, 85, 28-39.	2.1	0
65	Targeting myelin proteolipid protein to the MHC class I pathway by ubiquitination modulates the course of experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2008, 204, 92-100.	2.3	5
66	Role of CD5 ⁺ B-1 cells in EAE pathogenesis. Autoimmunity, 2008, 41, 353-362.	2.6	24
67	Cross-reactive myelin antibody induces renal pathology. Autoimmunity, 2008, 41, 526-536.	2.6	6
68	Regulatory Role of CD1d in Neurotropic Virus Infection. Journal of Virology, 2008, 82, 10279-10289.	3.4	23
69	Axonal degeneration as a selfâ€destructive defense mechanism against neurotropic virus infection. FASEB Journal, 2008, 22, 59.9.	0.5	Ο
70	Roles of CD1dâ€restricted V α 14 + NKT cells in Theiler's virus infection, a viral model for multiple sclerosis. FASEB Journal, 2008, 22, 856.6.	0.5	0
71	Infectious RNA Isolated from the Spinal Cords of Mice Chronically Infected with Theiler's Murine Encephalomyelitis Virus. Journal of Virology, 2007, 81, 3009-3011.	3.4	2
72	Molecular Mimicry in Multiple Sclerosis. International Review of Neurobiology, 2007, 79, 127-147.	2.0	74

#	Article	IF	CITATIONS
73	MOLECULAR MIMICRY. , 2007, , 13-19.		3
74	Contrasting Roles for Axonal Degeneration in an Autoimmune versus Viral Model of Multiple Sclerosis. American Journal of Pathology, 2007, 170, 214-226.	3.8	44
75	Targeting Inflammatory Demyelinating Lesions to Sites of Wallerian Degeneration. American Journal of Pathology, 2007, 171, 1563-1575.	3.8	40
76	Pathogenic epitopes, heterologous immunity and vaccine design. Nature Reviews Microbiology, 2007, 5, 555-563.	28.6	83
77	Modulation of Experimental Autoimmune Encephalomyelitis by VLA-2 Blockade. Brain Pathology, 2007, 17, 45-55.	4.1	35
78	Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis. Journal of Neuroimmunology, 2007, 184, 37-44.	2.3	161
79	Polyreactive myelin oligodendrocyte glycoprotein antibodies: Implications for systemic autoimmunity in progressive experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2007, 183, 69-80.	2.3	14
80	Sequential polymicrobial infections lead to CNS inflammatory disease: Possible involvement of bystander activation in heterologous immunity. Journal of Neuroimmunology, 2007, 188, 22-33.	2.3	17
81	TGF-β1 suppresses T cell infiltration and VP2 puff B mutation enhances apoptosis in acute polioencephalitis induced by Theiler's virus. Journal of Neuroimmunology, 2007, 190, 80-89.	2.3	21
82	Are there altered antibody responses to measles, mumps, or rubella viruses in autism?. Journal of NeuroVirology, 2007, 13, 252-259.	2.1	13
83	Multiple sclerosis and virus induced immune responses: Autoimmunity can be primed by molecular mimicry and augmented by bystander activation. Autoimmunity, 2006, 39, 9-19.	2.6	103
84	Autologous hematopoietic stem cell transplantation: a cure for multiple sclerosis?. Future Neurology, 2006, 1, 403-408.	0.5	3
85	Investigation of Treatment Failure in Neonatal Echovirus 7 Infection. Pediatric Infectious Disease Journal, 2006, 25, 259-262.	2.0	19
86	Hyperserotoninemia and Altered Immunity in Autism. Journal of Autism and Developmental Disorders, 2006, 36, 697-704.	2.7	50
87	IFN-Î ³ production and astrocyte recognition by autoreactive T cells induced by Theiler's virus infection: Role of viral strains and capsid proteins. Journal of Neuroimmunology, 2006, 172, 85-93.	2.3	22
88	Monoclonal MOG-reactive autoantibody from progressive EAE has the characteristics of a natural antibody. Journal of Neuroimmunology, 2006, 173, 135-145.	2.3	11
89	The pathologic role for COX-2 in apoptotic oligodendrocytes in virus induced demyelinating disease: Implications for multiple sclerosis. Journal of Neuroimmunology, 2006, 174, 21-31.	2.3	39
90	Molecular Mimicry, Bystander Activation, or Viral Persistence: Infections and Autoimmune Disease. Clinical Microbiology Reviews, 2006, 19, 80-94.	13.6	542

#	Article	IF	CITATIONS
91	Autistic disorder and viral infections. Journal of NeuroVirology, 2005, 11, 1-10.	2.1	196
92	Converting relapsing remitting to secondary progressive experimental allergic encephalomyelitis (EAE) by ultraviolet B irradiation. Journal of Neuroimmunology, 2005, 160, 122-134.	2.3	27
93	TMEV and Neuroantigens: Myelin Genes and Proteins, Molecular Mimicry, Epitope Spreading, and Autoantibody-Mediated Remyelination. , 2005, , 593-616.		10
94	Central Nervous System Pathology Caused by Autoreactive CD8 + T-Cell Clones following Virus Infection. Journal of Virology, 2005, 79, 14640-14646.	3.4	33
95	Massive Apoptosis in Lymphoid Organs in Animal Models for Primary and Secondary Progressive Multiple Sclerosis. American Journal of Pathology, 2005, 167, 1631-1646.	3.8	40
96	A tax on luxury: HTLV-I infection of CD4+CD25+ Tregs. Journal of Clinical Investigation, 2005, 115, 1144-1146.	8.2	1
97	Distinct roles for IP-10/C XC L10 in three animal models, Theiler's virus infection, EA E, and MHV infection, for multiple sclerosis: implication of differing roles for IP-10. Multiple Sclerosis Journal, 2004, 10, 26-34.	3.0	79
98	Manganese superoxide dismutase induction during measles virus infection. Journal of Medical Virology, 2003, 70, 470-474.	5.0	12
99	Microorganisms and autoimmunity: making the barren field fertile?. Nature Reviews Microbiology, 2003, 1, 151-157.	28.6	216
100	Axonal Injury Heralds Virus-Induced Demyelination. American Journal of Pathology, 2003, 162, 1259-1269.	3.8	103
101	Modulation of Immune System Function by Measles Virus Infection. II. Infection of B Cells Leads to the Production of a Soluble Factor That Arrests Uninfected B Cells in GO/G1. Viral Immunology, 2003, 16, 45-55.	1.3	14
102	Induction of Autoreactive CD8+ Cytotoxic T Cells during Theiler's Murine Encephalomyelitis Virus Infection: Implications for Autoimmunity. Journal of Virology, 2002, 76, 12834-12844.	3.4	47
103	Are virus infections triggers for autoimmune disease?. Clinical Microbiology Newsletter, 2002, 24, 73-76.	0.7	8
104	Inside-Out versus Outside-In models for virus induced demyelination: axonal damage triggering demyelination. Seminars in Immunopathology, 2002, 24, 105-125.	4.0	140
105	Molecular mimicry that primes for autoimmunity which is triggered by infection. Molecular Psychiatry, 2002, 7, S32-S33.	7.9	4
106	Altered Cell Growth and Morphology in a BHK-21 Cell Mutant That Lacks a Receptor for Theiler's Murine Encephalomyelitis Virus. Virology, 2002, 294, 85-93.	2.4	3
107	Mutation in loop I of VP1 of Theiler's virus delays viral RNA release into cells and enhances antibody-mediated neutralization: A mechanism for the failure of persistence by the mutant virus. Journal of NeuroVirology, 2002, 8, 100-110.	2.1	6
108	Can Virus Infections Trigger Autoimmune Disease?. Journal of Autoimmunity, 2001, 16, 229-234.	6.5	40

#	Article	IF	CITATIONS
109	Viruses and autoimmune disease – two sides of the same coin?. Trends in Microbiology, 2001, 9, 377-381.	7.7	37
110	DNA immunization and central nervous system viral infection. Advances in Virus Research, 2001, 56, 243-273.	2.1	1
111	Peripheral nerve protein, PO, as a potential receptor for Theiler's murine encephalomyelitis virus. Journal of NeuroVirology, 2001, 7, 97-104.	2.1	15
112	Viruses can silently prime for and trigger central nervous system autoimmune disease. Journal of NeuroVirology, 2001, 7, 220-227.	2.1	53
113	Prolonged Gray Matter Disease without Demyelination Caused by Theiler's Murine Encephalomyelitis Virus with a Mutation in VP2 Puff B. Journal of Virology, 2001, 75, 7494-7505.	3.4	44
114	Alterations in cytokine but not chemokine mRNA expression during three distinct Theiler's virus infections. Journal of Neuroimmunology, 2000, 104, 22-30.	2.3	66
115	Antibody Association with a Novel Model for Primary Progressive Multiple Sclerosis: Induction of Relapsingâ€Remitting and Progressive Forms of EAE in H2 ^S Mouse Strains. Brain Pathology, 2000, 10, 402-418.	4.1	81
116	Exacerbation of Viral and Autoimmune Animal Models for Multiple Sclerosis by Bacterial DNA. Brain Pathology, 1999, 9, 481-493.	4.1	95
117	Infection with a recombinant vaccinia virus encoding myelin proteolipid protein causes suppression of chronic relapsing–remitting experimental allergic encephalomyelitis. Journal of Neuroimmunology, 1999, 96, 148-157.	2.3	10
118	Contrasting effects of anti-adhesion molecule therapy in experimental allergic encephalomyelitis and Theiler's murine encephalomyelitis. Journal of Neuroimmunology, 1999, 97, 110-118.	2.3	18
119	Endogenous retroviruses: are they the cause of multiple sclerosis?. Trends in Microbiology, 1999, 7, 263-264.	7.7	16
120	Viruses as triggers of autoimmunity: facts and fantasies. Current Opinion in Microbiology, 1999, 2, 392-397.	5.1	42
121	DNA Vaccination against Theiler's Murine Encephalomyelitis Virus Leads to Alterations in Demyelinating Disease. Journal of Virology, 1999, 73, 993-1000.	3.4	22
122	Theiler's Viruses with Mutations in Loop I of VP1 Lead to Altered Tropism and Pathogenesis. Journal of Virology, 1999, 73, 2814-2824.	3.4	27
123	Suppression of Antigen-Specific T Cell Proliferation by Measles Virus Infection: Role of a Soluble Factor in Suppression. Virology, 1998, 246, 24-33.	2.4	50
124	Nitric oxide synthase inhibitor, aminoguanidine, reduces inflammation and demyelination produced by Theiler's virus infection. Journal of Neuroimmunology, 1998, 81, 82-89.	2.3	44
125	Gender variations in early Theiler's virus induced demyelinating disease: differential susceptibility and effects of IL-4, IL-10 and combined IL-4 with IL-10. Journal of Neuroimmunology, 1998, 85, 44-51.	2.3	45
126	Enhancement of Experimental Allergic Encephalomyelitis (EAE) by DNA Immunization with Myelin Proteolipid Protein (PLP) Plasmid DNA. Journal of Neuropathology and Experimental Neurology, 1998, 57, 758-767.	1.7	65

#	Article	IF	CITATIONS
127	Modulation of Immune System Function by Measles Virus Infection: Role of Soluble Factor and Direct Infection. Journal of Virology, 1998, 72, 9421-9427.	3.4	58
128	Replacement of Loop II of VP1 of the DA Strain with Loop II of the GDVII Strain of Theiler's Murine Encephalomyelitis Virus Alters Neurovirulence, Viral Persistence, and Demyelination. Journal of Virology, 1998, 72, 7557-7562.	3.4	14
129	Hydrocephalus in Mice Infected with a Theiler's Murine Encephalomyelitis Virus Variant. Journal of Neuropathology and Experimental Neurology, 1997, 56, 1302-1313.	1.7	43
130	Enhancement of EAE and induction of autoantibodies to T-cell epitopes in mice infected with a recombinant vaccinia virus encoding myelin proteolipid protein. Journal of Neuroimmunology, 1997, 75, 75-83.	2.3	34
131	Apoptosis in Acute and Chronic Central Nervous System Disease Induced by Theiler's Murine Encephalomyelitis Virus. Virology, 1997, 228, 388-393.	2.4	129
132	Measles Virus Infection of Human T Cells Modulates Cytokine Generation and IL-2 Receptor Alpha Chain Expression. Virology, 1997, 232, 241-247.	2.4	23
133	Lack of correlation of Theiler's virus binding to cells with infection. Journal of NeuroVirology, 1997, 3 Suppl 1, S68-70.	2.1	10
134	Virus encoding an encephalitogenic peptide protects mice from experimental allergic encephalomyelitis. Journal of Neuroimmunology, 1996, 64, 163-173.	2.3	28
135	Two Models for Multiple Sclerosis: Experimental Allergic Encephalomyelitis and Theiler's Murine Encephalomyelitis Virus. Journal of Neuropathology and Experimental Neurology, 1996, 55, 673-686.	1.7	176
136	Molecular Mimicry. , 1996, , 507-512.		3
137	Protection of SJL/J mice from demyelinating disease mediated by Theiler's murine encephalomyelitis virus. Microbial Pathogenesis, 1995, 18, 11-27.	2.9	23
138	Protection of SJL/J mice from demyelinating disease mediated by Theiler's murine encephalomyelitis virus. Microbial Pathogenesis, 1995, 18, 11-27.	2.9	5
139	B-lymphocyte requirement for vaccine-mediated protection from Theiler's murine encephalomyelitis virus-induced central nervous system disease. Journal of Virology, 1995, 69, 5152-5155.	3.4	17
140	Importance of amino acid 101 within capsid protein VP1 for modulation of Theiler's virus-induced disease. Journal of Virology, 1994, 68, 1219-1223.	3.4	32
141	Enhancement of autoimmune disease using recombinant vaccinia virus encoding myelin proteolipid protein. Journal of Neuroimmunology, 1993, 44, 15-25.	2.3	44
142	Viral infection and dissemination through the olfactory pathway and the limbic system by Theiler's virus. American Journal of Pathology, 1993, 143, 221-9.	3.8	29
143	Three-dimensional structure of Theiler virus Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 2061-2065.	7.1	96
144	Molecular mimicry: a mechanism for autoimmune injury ¹ . FASEB Journal, 1992, 6, 840-844.	0.5	91

#	Article	IF	CITATIONS
145	Pathogenesis of Theiler's Murine Encephalomyelitis Virus. Advances in Virus Research, 1991, 39, 291-320.	2.1	27
146	Common immunologic determinant between human immunodeficiency virus type 1 gp41 and astrocytes. Journal of Virology, 1991, 65, 1370-1376.	3.4	52
147	Direct evidence of a role for amino acid 101 of VP-1 in central nervous system disease in Theiler's murine encephalomyelitis virus infection. Journal of Virology, 1991, 65, 1929-1937.	3.4	65
148	Monoclonal antibody to Theiler's murine encephalomyelitis virus defines a determinant on myelin and oligodendrocytes, and augments demyelination in experimental allergic encephalomyelitis Journal of Experimental Medicine, 1990, 171, 1893-1907.	8.5	75
149	Alteration of amino acid 101 within capsid protein VP-1 changes the pathogenicity of Theiler's murine encephalomyelitis virus Journal of Experimental Medicine, 1989, 170, 2037-2049.	8.5	52
150	Virus-Induced Immunosuppression: Infection of Peripheral Blood Mononuclear Cells and Suppression of Immunoglobulin Synthesis During Natural Measles Virus Infection of Rhesus Monkeys. Journal of Infectious Diseases, 1989, 159, 757-760.	4.0	70
151	Molecular mimicry as a mechanism for virus-induced autoimmunity. Immunologic Research, 1989, 8, 3-15.	2.9	104
152	Is Theiler's murine encephalomyelitis virus infection of mice an autoimmune disease?. Apmis, 1989, 97, 1-8.	2.0	40
153	A neutralization-resistant Theiler's virus variant produces an altered disease pattern in the mouse central nervous system. Journal of Virology, 1989, 63, 1505-1513.	3.4	63
154	Survival of athymic (nu/nu) mice after Theiler's murine encephalomyelitis virus infection by passive administration of neutralizing monoclonal antibody. Journal of Virology, 1989, 63, 2081-2087.	3.4	69
155	Virus-Induced Autoimmunity Through Molecular Mimicry. Annals of the New York Academy of Sciences, 1988, 540, 210-217.	3.8	18
156	Monoclonal antibody defines determinant between Theiler's virus and lipid-like structures. Journal of Neuroimmunology, 1988, 20, 25-32.	2.3	54
157	Sequence homology and immunologic cross-reactivity of human cytomegalovirus with HLA-DR beta chain: a means for graft rejection and immunosuppression. Journal of Virology, 1988, 62, 100-105.	3.4	202
158	Theiler's virus infection in nude mice: viral RNA in vascular endothelial cells. Journal of Virology, 1988, 62, 3589-3596.	3.4	63
159	Viruses disrupt functions of human lymphocytes. II. Measles virus suppresses antibody production by acting on B lymphocytes. Journal of Experimental Medicine, 1986, 163, 1331-6.	8.5	34
160	Mechanism of Theiler's virus-induced demyelination in nude mice. Laboratory Investigation, 1986, 54, 515-22.	3.7	50
161	Amino Acid Homology Between the Encephalitogenic Site of Myelin Basic Protein and Virus: Mechanism for Autoimmunity. Science, 1985, 230, 1043-1045.	12.6	905
162	Antigenic modulation induced by monoclonal antibodies: antibodies to measles virus hemagglutinin alters expression of other viral polypeptides in infected cells. Journal of Immunology, 1984, 132, 2618-21.	0.8	25

#	Article	IF	CITATIONS
163	Antigenic Modulation: A Mechanism of Viral Persistence. Progress in Brain Research, 1983, 59, 105-111.	1.4	9
164	Molecular mimicry in virus infection: crossreaction of measles virus phosphoprotein or of herpes simplex virus protein with human intermediate filaments Proceedings of the National Academy of Sciences of the United States of America, 1983, 80, 2346-2350.	7.1	352
165	Failure to cleave measles virus fusion protein in lymphoid cells. A possible mechanism for viral persistence in lymphocytes. Journal of Experimental Medicine, 1981, 154, 1489-1499.	8.5	44
166	Immune reactive measles virus polypeptides on the cell's surface: turnover and relationship of the glycoproteins to each other and to HLA determinants. Journal of Immunology, 1981, 127, 935-40.	0.8	16
167	Alterations in expression of measles virus polypeptides by antibody: molecular events in antibody-induced antigenic modulation. Journal of Immunology, 1980, 125, 78-85.	0.8	102
168	Subacute sclerosing panencephalitis. , 0, , 26-34.		0
169	Virus-Induced Immunosuppression. , 0, , 375-387.		1
170	An Overview: Molecular Mimicry and Disease. , 0, , 1-16.		2
171	Peptide Mimicry of the Polysaccharide Capsule of Cryptococcus neoformans. , 0, , 143-160.		6
172	Molecular Mimicry: Lessons from Experimental Models of Systemic Lupus Erythematosus and Antiphospholipid Syndrome. , 0, , 223-233.		1
173	Molecular Mimicry and Chagas' Disease. , 0, , 257-274.		7
174	Principles of Molecular Mimicry and Autoimmune Disease. , 0, , 17-26.		3
175	Molecular Mimicry and Central Nervous System Autoimmune Disease. , 0, , 27-38.		3
176	Molecular Mimicry between Streptococcal M Protein and Cardiac Myosin and the Immunopathogenesis of Rheumatic Fever. , 0, , 39-56.		1
177	Antigenic Mimicry between Self and Coxsackievirus Proteins Leads to Both Humoral and Cellular Autoimmunity to Heart Proteins. , 0, , 57-68.		3
178	Role of Superantigens in Molecular Mimicry and Autoimmunity. , 0, , 95-107.		0
179	Exploiting Molecular Mimicry in Targeting Carbohydrate Antigens. , 0, , 175-196.		0
180	Molecular Mimicry and Determinant Spreading. , 0, , 215-222.		0

Molecular Mimicry and Determinant Spreading. , 0, , 215-222. 180

#	Article	IF	CITATIONS
181	Structural Basis of T-Cell Receptor Specificity and Cross-Reactivity: Implications for Pathogenesis of Human Autoimmune Diseases. , 0, , 197-213.		0
182	Mimicry between DNA, Carbohydrates, and Peptides: Implications in Systemic Lupus Erythematosus. , 0, , 127-141.		1
183	Peptide Mimicry of Streptococcal Group A Carbohydrate. , 0, , 83-94.		Ο
184	Peptide Induction of Systemic Lupus Autoimmunity. , 0, , 109-126.		0